M34.1 captures the limited form of systemic sclerosis defined by the combination of calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia — collectively known as CR(E)ST or CREST syndrome.
Verified May 8, 2026 · 6 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 0
- Region
- General
Documentation tips
What should appear in the chart to support M34.1.
Source · Editorial brief grounded in 6 cited references ↓
- Physician must document the specific CREST features present — at minimum two of the five defining components (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia) along with serological evidence such as positive anti-centromere antibodies.
- Record whether esophageal dysfunction is absent or subclinical; when it is absent, the variant is CRST syndrome — the ICD-10 Alphabetic Index maps both CRST and CREST to M34.1, but the distinction supports clinical specificity in the record.
- Document all organ-system manifestations separately: pulmonary, neuromuscular, and renal involvement each require additional codes (e.g., J99 for lung involvement, G73.7 for myopathy) — omitting them leaves reimbursable complexity uncoded.
- Note the treating specialty's confirmed diagnosis label (CREST syndrome, CR(E)ST syndrome, limited systemic sclerosis/scleroderma) explicitly in the assessment — vague language such as 'possible scleroderma' does not support M34.1 as a principal diagnosis in an outpatient setting.
- If Raynaud's is treated as a separate clinical problem at the same encounter, verify whether it is integral to the M34.1 diagnosis or an independently managed condition before adding a separate Raynaud's code.
Common coding pitfalls
The recurring mistakes coders make with M34.1 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning M34.9 (unspecified systemic sclerosis) when the documentation clearly supports CREST syndrome — M34.1 is more specific and required when the clinical picture fits.
- Coding M34.1 for localized scleroderma (morphea): L94.0 is the correct code; M34 category Excludes1 bars circumscribed scleroderma from this range entirely.
- Omitting manifestation codes for documented organ involvement: CREST syndrome frequently affects the lungs and GI tract, and failing to code those complications understates complexity and may trigger a medical necessity denial.
- Confusing M34.1 with M34.0 (progressive systemic sclerosis): M34.0 represents diffuse cutaneous systemic sclerosis with more aggressive progression — use M34.1 only when the provider documents the limited/CREST subtype.
- Submitting M34.1 as the supporting diagnosis for amniotic or placental-derived product injections: CMS LCD A59766 explicitly lists M34.1 among codes that do not support medical necessity for those procedures.
Clinical context
Source · Editorial summary grounded in 6 cited references ↓
M34.1 is the billable code for CR(E)ST syndrome, a limited variant of systemic sclerosis (scleroderma) in which fibrotic and vascular changes are predominantly confined to the skin distal to the elbows and knees, with characteristic multi-system features. The ICD-10-CM 'Applicable To' note specifies the full combination: calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia. When esophageal involvement is not prominent, the condition is sometimes called CRST syndrome — both CRST and CREST index directly to M34.1 in the Alphabetic Index.
Use M34.1 instead of M34.0 (progressive systemic sclerosis) when the treating physician documents limited cutaneous involvement consistent with CREST/CR(E)ST. Use M34.9 (systemic sclerosis, unspecified) only when the documentation does not support a more specific subtype. If organ-specific manifestations are documented beyond the five defining CREST features — for example, pulmonary fibrosis or myopathy — assign ancillary manifestation codes alongside M34.1 (e.g., J99 for lung involvement, G73.7 for myopathy in systemic sclerosis).
M34.1 sits under the M34 category, which carries an Excludes1 note for circumscribed scleroderma (L94.0) and neonatal scleroderma (P83.88). Do not assign M34.1 for localized morphea or neonatal presentations — those are categorically excluded. CMS has explicitly listed M34.1 among diagnoses that do not support medical necessity for amniotic/placental-derived product injections for musculoskeletal indications (LCD A59766), so payer policy review is essential before submitting procedure claims under this diagnosis.
Inclusion & exclusion notes
Per the official ICD-10-CM Tabular List.
Source · CDC ICD-10-CM Official Tabular List · 2026
Includes
- Combination of calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia
Sibling codes
Other billable codes under M34 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 6 cited references ↓
01What does the 'E' in parentheses in CR(E)ST syndrome mean?
02How many CREST features must be documented to use M34.1?
03Can M34.1 and M34.0 be coded together on the same claim?
04Should Raynaud's phenomenon be coded separately when M34.1 is assigned?
05Does M34.1 support medical necessity for amniotic or placental-derived product injections?
06What is the difference between M34.1 and L94.0?
07When should M34.8x manifestation codes be added alongside M34.1?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M34-/M34.1
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M34.1
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59766&ver=20
- 05cdek.pharmacy.purdue.eduhttps://cdek.pharmacy.purdue.edu/icd10/M34.1/
- 06icdcodes.aihttps://icdcodes.ai/diagnosis/crest-syndrome/documentation
Mira Scribe
Mira AI Scribe captures the specific CREST features documented at the encounter — which of the five components (calcinosis, Raynaud's, esophageal dysfunction, sclerodactyly, telangiectasia) are active, any positive serologic findings (anti-centromere antibodies), and organ-system involvement beyond the defining features. This prevents downcoding to unspecified systemic sclerosis (M34.9) and ensures manifestation codes for pulmonary or neuromuscular complications aren't missed.
See how Mira captures M34.1 documentation